Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

@article{SullivanChang2013TargetingCI,
  title={Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook},
  author={Loretta Sullivan-Chang and Robert T. O’Donnell and Joseph M Tuscano},
  journal={BioDrugs},
  year={2013},
  volume={27},
  pages={293-304}
}
CD22 is a B-cell-specific transmembrane glycoprotein found on the surface of most B cells; it modulates B-cell function, survival and apoptosis. CD22 has emerged as an ideal target for monoclonal antibody (mAb)-based therapy of B-cell malignancies including most lymphomas and many leukemias. Epratuzumab, an anti-CD22 mAb, has been developed in various forms, including as an unlabeled (naked) mAb, as a radioimmunotherapeutic, as an antibody drug conjugate (ADC), and as a vehicle for CD22… CONTINUE READING
17 Citations
79 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 79 references

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lym- phoblastic leukemia

  • J Kato
  • Leuk Res
  • 2012
Highly Influential
14 Excerpts

Southwest Oncology Group Study S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia

  • A Advani, S McDonough, +8 authors FR. Appelbaum
  • Presented at the 54th ASH Annual Meeting and…
  • 2012
Highly Influential
16 Excerpts

A novel anti-CD22 im- munotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL)

  • AS Wayne, D Bhojwani, +10 authors I. Pastan
  • Abstract 248, presented at the 53rd American…
  • 2011
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…